Here’s what I’m watching today…
I know, I know … I bashed Bit Digital Inc. (NASDAQ: BTBT) on Monday. But what I said about not trusting day-one moves on crypto stocks holds true. Stocks like BTBT and Marathon Digital Holdings Inc. (NASDAQ: MARA) are sketchy.
But bitcoin (BTC) is back above $40K, and it’s now day three of the moves. So yeah, I’m watching! I’m staying conservative since I’m concerned about bag-holders and selling pressure in the morning. But I’m on the lookout for midday or late-day moves…
A follower asked about Grove Inc. (NASDAQ: GRVI). This stock is in the weed/CBD sector. Ugh. Most of you know how I feel about weed plays…
All the same, it had a nice gap up. It’s a multi-month breakout. It’s got seven million float, and as of the premarket, it had traded four million shares. It’s an OK dip and rip contender, but I’m more dialed-in on the crypto plays today.
Low float stock Support.com, Inc. (NASDAQ: SPRT) has been squeezing for an entire week. It’s got good volume, and I like the current consolidation...
As of the premarket, I’m hoping it will chop around into the open. I’d consider $9.50 a good entry at any point today, with a risk at $9.
Sketchy biotech alert! Biondvax Pharmaceuticals Ltd. (NASDAQ: BVXV) is currently enjoying a truly disgusting gap down...
It’s probably due for a bounce, so I understand why some followers are watching it. But it’s really not my type of chart.
A lot of followers asked about sketchy biotechs today — don’t miss my discussion at the end of the session about why you’ve gotta be realistic about stocks like this. Never overstay!
As for charts that I’d stay away from? OTC play HPIL Holding Common Stock (OTCPK: HPIL). It’s not a breakout, so my standard approaches to OTCs don’t apply.
Intrusion Inc. (NASDAQ: INTZ) is another bag-holder chart. I’d avoid...
Apple Inc. (NASDAQ: AAPL) just crushed it on earnings. The problem with trading earnings is that they don’t always react in the obvious ways you might expect. It’s usually smart to wait and see the market’s reaction. That being said, I think it’s a potential weak open red-to-green.
A big warning about Chinese education plays like TAL Education Group (NYSE: TAL) … These plays are very risky. The headlines are terrible. They could get delisted at any time.
I beg you — look at plays like this as day trades only, not swing trades. Be careful!
🔴 Ready to learn more? Check out the SteadyTrade Team: https://stockstotrade.info/2UPC8Ww
🔴 Try StocksToTrade for $7: https://stockstotrade.info/2VkgBoo
🚀 Check out Small Cap Rockets: https://stockstotrade.com/small-cap-rockets/
📲 Download the STT app for iOS: https://apps.apple.com/us/app/stockstotrade-mobile/id1403963724
📲 Download the STT app for Android: https://play.google.com/store/apps/details?id=com.stockstotrade
🔴 Subscribe for more free Stock Trading tips: YouTube.com/StocksToTrade
👉Share this video with a fellow Trader: https://youtu.be/of6s97ui6IY
✅ Links we mention and recommend:
🔴Try StocksToTrade for $7: https://stockstotrade.info/2VkgBoo
🔴Get our FREE weekly watchlist here: https://stockstotrade.info/3l1gtVT
🔴Traders Blueprint Free Guide: https://stockstotrade.info/3i9dRDn
🔴Check out the SteadyTrade Podcast: https://steadytrade.com
🔴FREE StocksToTrade Market Grind: https://lp.stockstotrade.com/market-grind/
✅ Recommended playlists:
🔴SteadyTrade Podcast: http://bit.ly/2SXbrv7
🔴Stock Trading 101: A Day Trader's Guide: http://bit.ly/2sqs1ZZ
🔴Advanced Stock Trading Tips: http://bit.ly/3a32pTM
🔴Trader Spotlight with Tim Bohen: http://bit.ly/36TTzG3
🔴StocksToTrade Software Tips and Tricks: http://bit.ly/375GSry
🔴Weekly Trading Recap Videos: http://bit.ly/3a32uXA
🔴Charts and Patterns: http://bit.ly/2uj2KBO
✅ Follow StocksToTrade on social media:
Instagram: https://www.instagram.com/stockstotrade/
Facebook: https://www.facebook.com/StocksToTrade/
Twitter: https://twitter.com/StocksToTrade
#StockMarket #Stocks #PreMarketPrep
*Tim Bohen teaches skills others have used to make money. Most who receive free or paid content will make little or no money because they will not apply the skills being taught. Any results displayed may be exceptional. We do not guarantee any outcome regarding your earnings or income as the factors that impact such results are numerous and uncontrollable.
You can lose money trading stocks. Do not invest money you cannot afford to lose. You understand and agree you will consider the important risk factors in deciding to purchase any of our products or services.
I know, I know … I bashed Bit Digital Inc. (NASDAQ: BTBT) on Monday. But what I said about not trusting day-one moves on crypto stocks holds true. Stocks like BTBT and Marathon Digital Holdings Inc. (NASDAQ: MARA) are sketchy.
But bitcoin (BTC) is back above $40K, and it’s now day three of the moves. So yeah, I’m watching! I’m staying conservative since I’m concerned about bag-holders and selling pressure in the morning. But I’m on the lookout for midday or late-day moves…
A follower asked about Grove Inc. (NASDAQ: GRVI). This stock is in the weed/CBD sector. Ugh. Most of you know how I feel about weed plays…
All the same, it had a nice gap up. It’s a multi-month breakout. It’s got seven million float, and as of the premarket, it had traded four million shares. It’s an OK dip and rip contender, but I’m more dialed-in on the crypto plays today.
Low float stock Support.com, Inc. (NASDAQ: SPRT) has been squeezing for an entire week. It’s got good volume, and I like the current consolidation...
As of the premarket, I’m hoping it will chop around into the open. I’d consider $9.50 a good entry at any point today, with a risk at $9.
Sketchy biotech alert! Biondvax Pharmaceuticals Ltd. (NASDAQ: BVXV) is currently enjoying a truly disgusting gap down...
It’s probably due for a bounce, so I understand why some followers are watching it. But it’s really not my type of chart.
A lot of followers asked about sketchy biotechs today — don’t miss my discussion at the end of the session about why you’ve gotta be realistic about stocks like this. Never overstay!
As for charts that I’d stay away from? OTC play HPIL Holding Common Stock (OTCPK: HPIL). It’s not a breakout, so my standard approaches to OTCs don’t apply.
Intrusion Inc. (NASDAQ: INTZ) is another bag-holder chart. I’d avoid...
Apple Inc. (NASDAQ: AAPL) just crushed it on earnings. The problem with trading earnings is that they don’t always react in the obvious ways you might expect. It’s usually smart to wait and see the market’s reaction. That being said, I think it’s a potential weak open red-to-green.
A big warning about Chinese education plays like TAL Education Group (NYSE: TAL) … These plays are very risky. The headlines are terrible. They could get delisted at any time.
I beg you — look at plays like this as day trades only, not swing trades. Be careful!
🔴 Ready to learn more? Check out the SteadyTrade Team: https://stockstotrade.info/2UPC8Ww
🔴 Try StocksToTrade for $7: https://stockstotrade.info/2VkgBoo
🚀 Check out Small Cap Rockets: https://stockstotrade.com/small-cap-rockets/
📲 Download the STT app for iOS: https://apps.apple.com/us/app/stockstotrade-mobile/id1403963724
📲 Download the STT app for Android: https://play.google.com/store/apps/details?id=com.stockstotrade
🔴 Subscribe for more free Stock Trading tips: YouTube.com/StocksToTrade
👉Share this video with a fellow Trader: https://youtu.be/of6s97ui6IY
✅ Links we mention and recommend:
🔴Try StocksToTrade for $7: https://stockstotrade.info/2VkgBoo
🔴Get our FREE weekly watchlist here: https://stockstotrade.info/3l1gtVT
🔴Traders Blueprint Free Guide: https://stockstotrade.info/3i9dRDn
🔴Check out the SteadyTrade Podcast: https://steadytrade.com
🔴FREE StocksToTrade Market Grind: https://lp.stockstotrade.com/market-grind/
✅ Recommended playlists:
🔴SteadyTrade Podcast: http://bit.ly/2SXbrv7
🔴Stock Trading 101: A Day Trader's Guide: http://bit.ly/2sqs1ZZ
🔴Advanced Stock Trading Tips: http://bit.ly/3a32pTM
🔴Trader Spotlight with Tim Bohen: http://bit.ly/36TTzG3
🔴StocksToTrade Software Tips and Tricks: http://bit.ly/375GSry
🔴Weekly Trading Recap Videos: http://bit.ly/3a32uXA
🔴Charts and Patterns: http://bit.ly/2uj2KBO
✅ Follow StocksToTrade on social media:
Instagram: https://www.instagram.com/stockstotrade/
Facebook: https://www.facebook.com/StocksToTrade/
Twitter: https://twitter.com/StocksToTrade
#StockMarket #Stocks #PreMarketPrep
*Tim Bohen teaches skills others have used to make money. Most who receive free or paid content will make little or no money because they will not apply the skills being taught. Any results displayed may be exceptional. We do not guarantee any outcome regarding your earnings or income as the factors that impact such results are numerous and uncontrollable.
You can lose money trading stocks. Do not invest money you cannot afford to lose. You understand and agree you will consider the important risk factors in deciding to purchase any of our products or services.
Thank you Tim
thank u tim
Of course every beginner will panic and stop holding because they have a entry and exit plan to ride price fluctuations.
Do you execute your trades through stocks to trade?
Agenus Inc. (AGEN) PT Raised to $11 at B.RILEY
Current stock price is $4.90
Agenus (ticker symbol AGEN) is an immuno-therapy clinical stage company. They also produce vaccines and cell therapy (INKT’S) through their subsidiary company Agentus.
Agenus recently announced the confidential submission for proposed IPO of its subsidiary company, MiNk Therapeutics. Shareholders will be happy to hear this long awaited good news!
Their main product and near future revenue generators are their PD-1 and CTLA-4 CPMS. The FDA just recently accepted priority review for the BLA filing of AGEN2034, their PD-1 molecule in second line cervical cancer. They have a PDUFA date set for December 16, 2021. They’re also on track for a BLA filing with their PD-1 and first generation CTLA-4 in combination for the same indication. Agenus’s PD-1 has shown clinical proof to be differentiated from the other PD-1’s that are already out there on the market; mainly it’s superiority over keytruda (in second line CC). More importantly, Agenus’s PD-1 works in both PD-L1 positive AND negative tumors. Keytruda’s does not.
Agenus also has the most powerful adjuvant (QS-21 stimulon) on the market. Not to be confused with the other QS-21’s that are out there. QS-21 stimulon is basically an ingredient that increases the efficacy of a vaccine/drug (COVID-19?) QS-21 stimulon is one of the main reasons why GSK’s shingrix vaccine has taken up most of the market share. Agenus is currently working on getting funding from the government to rapidly increase production.
Agenus is partnered with Incyte, Merck, Gilead, Glaxosmithkline and most recently, Bristol Myers Squibb. Agenus set a previous record for money given for three preclinical molecules with Gilead for ~150m upfront cash (30m in equity) along with future potential royalties and milestones worth around ~1.7B. However this year, BMY beat that figure by acquiring only one preclinical molecule which is a TIGIT BISPECIFIC to the tune of ~200m along with future potential milestones and royalties worth ~1.36B
However, the most exciting molecule they have could be a potential multi blockbuster which is their next generation CTLA-4 AGEN1181. This is what most investors are banking on. It’s currently in phase 2. It was generating partial and complete responses in phase 1 which is very promising ‘cause phase 1 is administered in low dosage to monitor toxicity levels and showing very promising results. Ctla-4 is notorious for being toxic but agenus has manufactured a version that has sustained tolerable toxicity levels. This is huge. They will be presenting data at the next big venue which will either be at ESMO in September or SITC in December.
They have a vast pipeline for such a small company. Probably the most robust pipeline out of any company their size.
Finally, they have a clinical trial with their INKT cell therapy that’s showing positive signs in patients with severe symptoms from COVID-19. So far, 3 out of 4 patients have been extubated (taken off ventilators) within 24 hours. These trials have been running a little slow but they’re expecting additional clinical data soon. However, COVID-19 is not their primary objective with INKT’s. It was nearly an afterthought during the pandemic. Their INKT’s will mainly target Cancer cells.
Final note: institutions have recently taken more of an interest in Agenus. I believe institutional holdings have increased by over 10 percent. Agenus has about ~319m in cash as of last quarter which would give them about roughly 2 years of cash runway. GLTALS
Agenus Inc. (AGEN) PT Raised to $11 at B.RILEY
Current stock price is $4.90
Agenus (ticker symbol AGEN) is an immuno-therapy clinical stage company. They also produce vaccines and cell therapy (INKT’S) through their subsidiary company Agentus.
Agenus recently announced the confidential submission for proposed IPO of its subsidiary company, MiNk Therapeutics. Shareholders will be happy to hear this long awaited good news!
Their main product and near future revenue generators are their PD-1 and CTLA-4 CPMS. The FDA just recently accepted priority review for the BLA filing of AGEN2034, their PD-1 molecule in second line cervical cancer. They have a PDUFA date set for December 16, 2021. They’re also on track for a BLA filing with their PD-1 and first generation CTLA-4 in combination for the same indication. Agenus’s PD-1 has shown clinical proof to be differentiated from the other PD-1’s that are already out there on the market; mainly it’s superiority over keytruda (in second line CC). More importantly, Agenus’s PD-1 works in both PD-L1 positive AND negative tumors. Keytruda’s does not.
Agenus also has the most powerful adjuvant (QS-21 stimulon) on the market. Not to be confused with the other QS-21’s that are out there. QS-21 stimulon is basically an ingredient that increases the efficacy of a vaccine/drug (COVID-19?) QS-21 stimulon is one of the main reasons why GSK’s shingrix vaccine has taken up most of the market share. Agenus is currently working on getting funding from the government to rapidly increase production.
Agenus is partnered with Incyte, Merck, Gilead, Glaxosmithkline and most recently, Bristol Myers Squibb. Agenus set a previous record for money given for three preclinical molecules with Gilead for ~150m upfront cash (30m in equity) along with future potential royalties and milestones worth around ~1.7B. However this year, BMY beat that figure by acquiring only one preclinical molecule which is a TIGIT BISPECIFIC to the tune of ~200m along with future potential milestones and royalties worth ~1.36B
However, the most exciting molecule they have could be a potential multi blockbuster which is their next generation CTLA-4 AGEN1181. This is what most investors are banking on. It’s currently in phase 2. It was generating partial and complete responses in phase 1 which is very promising ‘cause phase 1 is administered in low dosage to monitor toxicity levels and showing very promising results. Ctla-4 is notorious for being toxic but agenus has manufactured a version that has sustained tolerable toxicity levels. This is huge. They will be presenting data at the next big venue which will either be at ESMO in September or SITC in December.
They have a vast pipeline for such a small company. Probably the most robust pipeline out of any company their size.
Finally, they have a clinical trial with their INKT cell therapy that’s showing positive signs in patients with severe symptoms from COVID-19. So far, 3 out of 4 patients have been extubated (taken off ventilators) within 24 hours. These trials have been running a little slow but they’re expecting additional clinical data soon. However, COVID-19 is not their primary objective with INKT’s. It was nearly an afterthought during the pandemic. Their INKT’s will mainly target Cancer cells.
Final note: institutions have recently taken more of an interest in Agenus. I believe institutional holdings have increased by over 10 percent. Agenus has about ~319m in cash as of last quarter which would give them about roughly 2 years of cash runway. GLTALS
Thank you Tim
Preciate you Tim and all of your efforts! I'm looking into your programs. I already have STT. I'll have some good ones for your with thorough research…I'm learning.📚💪🏾👏🏾🔥